National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

Catharine M. Sturgeon, Michael J. Duffy, Ulf Håkan Stenman, Hans Lilja, Nils Brünner, Daniel Wan-Yui Chan, Richard Babaian, Robert C. Bast, Barry Dowell, Francisco J. Esteva, Caj Haglund, Nadia Harbeck, Daniel F. Hayes, Mads Holten-Andersen, George G. Klee, Rolf Lamerz, Leendert H. Looijenga, Rafael Molina, Hans Jørgen Nielsen, Harry Rittenhouse & 8 others Axel Semjonow, Ie Ming Shih, Paul Sibley, György Sölétormos, Carsten Stephan, Lori J Sokoll, Barry R. Hoffman, Eleftherios P. Diamandis

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites - testicular, prostate, colorectal, breast, and ovarian - were critically reviewed. RESULTS: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is

Original languageEnglish (US)
JournalClinical Chemistry
Volume54
Issue number12
DOIs
StatePublished - Dec 1 2008

Fingerprint

Biochemistry
Testicular Neoplasms
Prostate-Specific Antigen
Tumor Biomarkers
Practice Guidelines
Ovarian Neoplasms
Fetal Proteins
Medicine
Colorectal Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Prostatic Diseases
Recurrence
Monitoring
Chorionic Gonadotropin
Early Detection of Cancer
L-Lactate Dehydrogenase
Tumors
Prostate
Screening

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. / Sturgeon, Catharine M.; Duffy, Michael J.; Stenman, Ulf Håkan; Lilja, Hans; Brünner, Nils; Chan, Daniel Wan-Yui; Babaian, Richard; Bast, Robert C.; Dowell, Barry; Esteva, Francisco J.; Haglund, Caj; Harbeck, Nadia; Hayes, Daniel F.; Holten-Andersen, Mads; Klee, George G.; Lamerz, Rolf; Looijenga, Leendert H.; Molina, Rafael; Nielsen, Hans Jørgen; Rittenhouse, Harry; Semjonow, Axel; Shih, Ie Ming; Sibley, Paul; Sölétormos, György; Stephan, Carsten; Sokoll, Lori J; Hoffman, Barry R.; Diamandis, Eleftherios P.

In: Clinical Chemistry, Vol. 54, No. 12, 01.12.2008.

Research output: Contribution to journalArticle

Sturgeon, CM, Duffy, MJ, Stenman, UH, Lilja, H, Brünner, N, Chan, DW-Y, Babaian, R, Bast, RC, Dowell, B, Esteva, FJ, Haglund, C, Harbeck, N, Hayes, DF, Holten-Andersen, M, Klee, GG, Lamerz, R, Looijenga, LH, Molina, R, Nielsen, HJ, Rittenhouse, H, Semjonow, A, Shih, IM, Sibley, P, Sölétormos, G, Stephan, C, Sokoll, LJ, Hoffman, BR & Diamandis, EP 2008, 'National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers', Clinical Chemistry, vol. 54, no. 12. https://doi.org/10.1373/clinchem.2008.105601
Sturgeon, Catharine M. ; Duffy, Michael J. ; Stenman, Ulf Håkan ; Lilja, Hans ; Brünner, Nils ; Chan, Daniel Wan-Yui ; Babaian, Richard ; Bast, Robert C. ; Dowell, Barry ; Esteva, Francisco J. ; Haglund, Caj ; Harbeck, Nadia ; Hayes, Daniel F. ; Holten-Andersen, Mads ; Klee, George G. ; Lamerz, Rolf ; Looijenga, Leendert H. ; Molina, Rafael ; Nielsen, Hans Jørgen ; Rittenhouse, Harry ; Semjonow, Axel ; Shih, Ie Ming ; Sibley, Paul ; Sölétormos, György ; Stephan, Carsten ; Sokoll, Lori J ; Hoffman, Barry R. ; Diamandis, Eleftherios P. / National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. In: Clinical Chemistry. 2008 ; Vol. 54, No. 12.
@article{2f2b53d1f8d6418f9a77a446d79c0356,
title = "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers",
abstract = "BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites - testicular, prostate, colorectal, breast, and ovarian - were critically reviewed. RESULTS: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is",
author = "Sturgeon, {Catharine M.} and Duffy, {Michael J.} and Stenman, {Ulf H{\aa}kan} and Hans Lilja and Nils Br{\"u}nner and Chan, {Daniel Wan-Yui} and Richard Babaian and Bast, {Robert C.} and Barry Dowell and Esteva, {Francisco J.} and Caj Haglund and Nadia Harbeck and Hayes, {Daniel F.} and Mads Holten-Andersen and Klee, {George G.} and Rolf Lamerz and Looijenga, {Leendert H.} and Rafael Molina and Nielsen, {Hans J{\o}rgen} and Harry Rittenhouse and Axel Semjonow and Shih, {Ie Ming} and Paul Sibley and Gy{\"o}rgy S{\"o}l{\'e}tormos and Carsten Stephan and Sokoll, {Lori J} and Hoffman, {Barry R.} and Diamandis, {Eleftherios P.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1373/clinchem.2008.105601",
language = "English (US)",
volume = "54",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "12",

}

TY - JOUR

T1 - National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

AU - Sturgeon, Catharine M.

AU - Duffy, Michael J.

AU - Stenman, Ulf Håkan

AU - Lilja, Hans

AU - Brünner, Nils

AU - Chan, Daniel Wan-Yui

AU - Babaian, Richard

AU - Bast, Robert C.

AU - Dowell, Barry

AU - Esteva, Francisco J.

AU - Haglund, Caj

AU - Harbeck, Nadia

AU - Hayes, Daniel F.

AU - Holten-Andersen, Mads

AU - Klee, George G.

AU - Lamerz, Rolf

AU - Looijenga, Leendert H.

AU - Molina, Rafael

AU - Nielsen, Hans Jørgen

AU - Rittenhouse, Harry

AU - Semjonow, Axel

AU - Shih, Ie Ming

AU - Sibley, Paul

AU - Sölétormos, György

AU - Stephan, Carsten

AU - Sokoll, Lori J

AU - Hoffman, Barry R.

AU - Diamandis, Eleftherios P.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites - testicular, prostate, colorectal, breast, and ovarian - were critically reviewed. RESULTS: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is

AB - BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites - testicular, prostate, colorectal, breast, and ovarian - were critically reviewed. RESULTS: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is

UR - http://www.scopus.com/inward/record.url?scp=55349134617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349134617&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2008.105601

DO - 10.1373/clinchem.2008.105601

M3 - Article

VL - 54

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 12

ER -